Repare Therapeutics


Repare has developed and deployed a proprietary, high-throughput, genomic and chemo-genomic synthetic lethal screening platform that starts and ends with the patient in mind, identifying important mutations (“lesions”) in the clinic that identify the target patient populations most likely to respond to its precision medicines. The platform harnesses the power of CRISPR/Cas9 genome editing to identify promising new targets for rapid small molecule drug discovery, leveraging high-resolution protein crystallography, advanced informatics, and the unprecedented ability to exploit DNA Damage Response (DDR) defects and genome instability found across virtually all cancers.

See all Members